Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study

BACKGROUND: Eculizumab, a terminal complement inhibitor, is approved for atypical haemolytic uraemic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). METHODS: In five parent studies, eculizumab effectively prevented TMA and improved renal and haematologic outcomes in...

Descripción completa

Detalles Bibliográficos
Autores principales: Menne, Jan, Delmas, Yahsou, Fakhouri, Fadi, Kincaid, John F, Licht, Christoph, Minetti, Enrico E, Mix, Chris, Provôt, François, Rondeau, Eric, Sheerin, Neil S, Wang, Jimmy, Weekers, Laurent E, Greenbaum, Larry A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Atypical Hemolytic Uremic Syndrome
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452204/
https://www.ncbi.nlm.nih.gov/pubmed/30976396
http://dx.doi.org/10.1093/ckj/sfy035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452204/
https://www.ncbi.nlm.nih.gov/pubmed/30976396
http://dx.doi.org/10.1093/ckj/sfy035

Ejemplares similares